Induction of Complete Haematological Remission After Monotherapy with AntLCD20 Monoclonal Antibody (RITUXIMAB) in a Patient with Alkylating Agent Resistant Waldenstrom's Macroglobulinaemia
- 1 January 1999
- journal article
- case report
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 36 (1) , 203-206
- https://doi.org/10.3109/10428199909145966
Abstract
Response of Waldenström's macroglobulinaemia to chemotherapy with alkylating agents is usually only transient. We report a case with marked bone marrow involvement and resistance to chemotherapy with alkylating agents. The patient was red cell and platelet transfusion dependent. Three weeks after rituximab-monotherapy, he achieved a complete haematological remission which is continuing 6 months after the end of therapy. Our case demonstrates that treatment with the unconjugated anti-CD20-monoclonal antibody (rituximab) may be a new powerful tool for a better treatment of Waldenström's macroglobulinaemia.Keywords
This publication has 6 references indexed in Scilit:
- Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemiaAnnals of Oncology, 1996
- Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphomaBlood, 1994
- Waldenstrom's macroglobulinemiaBlood, 1994
- Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20Blood, 1994
- The Spectrum of IgM Monoclonal Gammopathy in 430 CasesMayo Clinic Proceedings, 1987
- Analysis of leucocyte differentiation antigens in blood and bone marrow from patients with Waldenström's macroglobulinaemiaBritish Journal of Haematology, 1987